Jean You, MD
Pain Medicine · Kennewick, WANPI 1184660029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,699 and has fallen 78.9% since, to $358 in 2025.
Across 410 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Daiichi Sankyo Inc.$1K
- Collegium Pharmaceutical, Inc.$896
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$873
- Biodelivery Sciences International, Inc.$509
- Biohaven Pharmaceuticals, Inc.$484
- plus $1K from 17 others
What the payments were for
- Food & beverage$6,397100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,103 |
| Daiichi Sankyo Inc. | 100 | $1,099 |
| Collegium Pharmaceutical, Inc. | 57 | $896 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $873 |
| Biodelivery Sciences International, Inc. | 35 | $509 |
| Biohaven Pharmaceuticals, Inc. | 23 | $484 |
| Nusmile, Ltd. | 1 | $268 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $247 |
| Lilly USA, LLC | 18 | $247 |
| Pfizer | 11 | $200 |
| Teva Pharmaceuticals USA, Inc. | 4 | $122 |
| Amgen | 3 | $74 |
| Merz Pharmaceuticals, LLC | 2 | $41 |
| Eisai Inc. | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $36 |
| Zyla Life Sciences, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 1 | $29 |
| Novartis | 2 | $26 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SleeperOne$268
- Morphabond ER$115
How this compares
$6,418 in reported general payments places this provider in the 70th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 285 | $255,616 |
| Buprenorphine | 182 | $44,508 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,738 | $41,417 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 322 | $35,322 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $25,787 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 808 | $23,359 |
| Nurtec OdtRimegepant Sulfate | 15 | $20,837 |
| OxycontinOxycodone Hcl | 40 | $15,491 |
| Pregabalin | 532 | $11,829 |
| UbrelvyUbrogepant | 12 | $11,647 |
| NucyntaTapentadol Hcl | 11 | $9,983 |
| Gabapentin | 605 | $9,877 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,709 |
| Fentanyl | 78 | $6,211 |
| Buprenorphine Hcl | 150 | $4,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta | $896 | $265,599296 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate | $21 | $86,057695 claims |
| Indivior Inc.Suboxone | $20 | $25,78731 claims |
| PfizerNurtec Odt | $200 | $20,83715 claims |
| AbbVieUbrelvy | $1,103 | $11,64712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 124 pain medicine providers in Washington.
Other pain medicine in Kennewick
- Nicholas JuanKennewick$10K
- Jennifer LeeKirkland$318K
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Caroline HarstroemEverett$74K
- Sloane YuVancouver$42K
- Praveen MambalamEdmonds$32K
- Miroslav BackonjaSeattle$22K
- Ross VogelgesangOlympia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.